Therapy in Medical Technology

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

PHOENIX, Aug. 3 /PRNewswire-USNewswire/ -- The Phoenix-based Kronos Longevity Research Institute (KLRI) has published two new publications on hormone therapies and their effects on reducing the risks of cardiovascular disease in older adults. Cardiovascular disease caused by ...

Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window

Findings May Potentially Lead to New Approach to Stroke Treatment BOCA RATON, Fla., July 30 /PRNewswire-USNewswire/ -- When minimally invasive endovascular (through the vessel) therapy made its debut two decades ago, stroke care underwent a major shift as the "window of treatmen...

ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases

BLACK MOUNTAIN, N.C., June 24 /PRNewswire/ -- ALP Life Sciences, LLC (Company) today announced the Nanoveson(TM) patent has been filed and the Nanoveson(TM) whitepaper is available at www.ALPLifeSciences.com/wp . After completing initial research, the Company is pursuing clinical trials an...

New Therapy Found to Prevent Heart Failure

ROCHESTER, N.Y., June 23 /PRNewswire-USNewswire/ -- A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization therapy device with defibrillator (CRT-D) versus patients who recei...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

SEATTLE, June 22 /PRNewswire-FirstCall/ -- Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups Additional Clinical Studies Also Highlighted at Pan ...

CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement

CardioVascularCS.Org and CICT collaborate by reconstructing cardiovascular clinical experiences presented virtually at the annual CICT conference BOSTON, June 2 /PRNewswire/ -- The EndoVascular Forum, Inc. (EVF), an IC Sciences Company, and its partner Complex Interventional Cardiovascular T...

Three Independent Studies Include the ImmuKnow(R) Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients

The results of these studies will be presented during the American Transplant Congress in Boston, MA May 30 - June 3, 2009 COLUMBIA, Md., May 31 /PRNewswire/ -- A study conducted at Westchester Medical Center in Valhalla, NY examined liver transplant recipients to determine whether the use o...

Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting

Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients; Phase 2 Study Currently Enrolling in 17 Leading U.S. Medical Centers SAN DIEGO, May 28 /PRNewswire/ -- Celladon Corporation presented today Phase 1 data from the Calcium Up-Regulation by Percutaneou...

New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer

--In a First, Immunotherapy Works Against Neuroblastoma-- PHILADELPHIA, May 28 /PRNewswire-USNewswire/ -- A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma...

MitraClip(R) Therapy Data Demonstrate Clinical Benefit in High-Risk Patients With Mitral Regurgitation

EVEREST High-Risk Registry Data Show Improved Symptomatic Status, Cardiac Function and Reduced rate of Hospitalization for Congestive Heart Failure in both Functional and Degenerative MR Patient Populations BARCELONA, Spain, May 20 /PRNewswire/ -- Results show percutaneous mitral repair using...

New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure

PARSIPPANY, N.J., May 8 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that new data presented at the American Society of Hypertension, Inc. (ASH) Annual Scientific Meeting and Exposition (ASH 2009) in San Francisco from the BeniSILVER study found that BENICAR (R) and BENICAR HCT (R) pro...

Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients

OXFORD, England, April 21 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced today that it has initiated a phase II clinical study of its ToleroMune(R) technology in allergy patients with asthma. The trial builds on positive phase II results that...

Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects

LEWISVILLE, N.C., April 20 /PRNewswire/ -- Muscadine grape skin powder, from Muscadine Naturals, Inc , (http:// www.muscadinenaturals.com /), provided significant protection against radiation damage in an independent study conducted on mice. The finding was reported in April of 2009 at the 1...

MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up

EVEREST High-Risk Registry Data Shows Improved Symptomatic Status and Cardiac Function in Functional MR Patients Treated with the MitraClip(R) System ORLANDO, Fla., March 28 /PRNewswire/ -- Percutaneous mitral valve repair using the MitraClip(R) system in symptomatic high-risk surgical patien...

Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers

FORT WORTH, Texas, March 16 /PRNewswire/ -- Healthpoint today announced that it has initiated a Phase II clinical trial investigating the efficacy of HP802-247 in venous leg ulcers. HP802-247 is a topical spray containing living keratinocytes and fibroblasts. The study is designed to determine the...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

New use for PEGINTRON(TM) and REBETOL(R) offers certain patients a second chance to achieve treatment success KENILWORTH, N.J., March 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug Administration (FDA) has approved new label...

Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study

Participants Sought For Landmark Study To Measure Effects Of Music On Diabetes Outcomes PAINESVILLE, Ohio, March 11 /PRNewswire/ -- Lake Hospital System today announced that it has received a $60,000 grant from the Kulas Foundation to support a groundbreaking study that will measure th...

Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production

Dermatologist evaluates the latest laser and light sources approved for treating acne SAN FRANCISCO, March 5 /PRNewswire-USNewswire/ -- From the removal of childhood birthmarks to skin rejuvenation, laser technology has become a mainstay in dermatology. Now, dermatologists are fine-tuning t...

Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease

Surveyed Neurologists and PCPs Vary in Their Prescribing Patterns of Levodopa/Carbidopa and Dopamine Agonists, According to a New Report from Decision Resources WALTHAM, Mass., March 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharm...

Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year

LITTLETON, Mass., Feb. 26 /PRNewswire/ -- Still River Systems announced today the successful operation of the world's highest field, high energy cyclotron magnet. Still River's magnet is the key technical element for reducing the size and cost of the particle accelerator that will deliver proton t...

A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe

Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare is...

New Proton Therapy Equipment Enables More Tumors to be Treated

JACKSONVILLE, Fla. Feb. 23 /PRNewswire/ -- An advance in the way protons are delivered at the University of Florida Proton Therapy Institute enables physicians to treat tumors that are deeper in the body, tumors that are very large and tumors that are situated closer to vital organs. Calle...

New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years

DÿSSELDORF, Germany, February 23 /PRNewswire/ -- An international team of researchers has evaluated the effectiveness of Orthokine therapy for osteoarthritis of the knee, and the results have been published in the February edition of the specialist journal "Osteoarthritis and Cartilage". The ...

Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration

CALGARY, Feb. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) and the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA) announced a broad preclinical and clinical collaboration invol...

Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer

SAN FRANCISCO, Jan. 20 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (Nasdaq: IMMU ) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that results presented at the 2009 Gastrointestinal Cancers Symposium showed ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

SAN ANTONIO, Dec. 14 /PRNewswire/ -- Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after r...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results based on extended follow up of patients from the large, international Phase III VISTA(1) trial showing continued survival improvement for patients with previously untreated multiple myeloma...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

Tasigna now shows potential to become the treatment of choice for certain newly diagnosed patients with chronic myeloid leukemia Two separate studies show rapid elimination of cancer cells in 96% of Tasigna patients and reduction of abnormal CML protein by six months ...

Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months

SEATTLE, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that extended follow-up data for the Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent (FIT) study presented at the American Society of Hematology (ASH) 50th Annual Meeting by M...

Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures

SEATTLE, Dec. 6 /PRNewswire/ -- Phase III data on carisbamate, an investigational compound recently filed with the FDA for the adjunctive treatment of partial onset seizures (POS) in patients 16 years of age and older, was presented today during the poster sessions of the 32nd Annual Meeting of th...

Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial

PLEASANTON, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR ), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that a pre-specified interim analysis of data from its HeartMate II Destinati...

Gene Therapy Corrects Sickle Cell Disease in Laboratory Study

New St. Jude treatment alleviates long-term anemia and organ damage in mice and paves the way for human applications MEMPHIS, Tenn., Dec. 3 /PRNewswire-USNewswire/ -- Using a harmless virus to insert a corrective gene into mouse blood cells, scientists at St. Jude Children's Research Hos...

Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

CARLSBAD, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that OncoGenex Pharmaceuticals, Inc. provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm...

Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease

MIAMI, Nov. 12 /PRNewswire/ -- The Miami Jewish Home and Hospital, Berma Research Group, and Segal Institute for Clinical Research today announced that they are actively enrolling patients in the CONNECTION study, a Phase 3 clinical trial that is evaluating the safety and efficacy of the inves...

Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells

BETHESDA, Md., Nov. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a preclinical study(1) showing cytotoxic activity of anti-E...

Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults

- Ninety-six week ARTEMIS data presented at ICAAC - BRIDGEWATER, N.J., Oct. 26 /PRNewswire/ -- Ninety-six week results presented today from a phase 3, randomized, open-label, ongoing clinical trial showed that 79 percent of treatment-naive HIV-1 infected adults taking PREZISTA(R) 800 mg (t...

Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer

Despite Widespread Use, Formulary Coverage of Targeted Cancer Therapies is Inconsistent, According to a New Report from Decision Resources WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issu...

Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS)

SWARTZ CREEK, Mich., Oct. 10 /PRNewswire/ -- Diplomat Specialty Pharmacy announced today that Teva Neuroscience has selected Diplomat Specialty Pharmacy to be one of only three sites to participate in a large scale, national Therapy Optimization Study for Multiple Sclerosis (TOP MS). The goa...

NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting

Long-Term Phase II Data Continue to Highlight Potential of NeoVista's Epiretinal Brachytherapy SCOTTSDALE, Ariz., Sept. 29 /PRNewswire/ -- NeoVista, Inc. made public yesterday 18-month data from the company's Phase II feasibility study examining its novel epiretinal bra...

Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence

Study Shows near 80% Improvement In Outcomes PITTSBURGH, Sept. 23 /PRNewswire/ -- Radiation oncologists at Allegheny General Hospital (AGH) in Pittsburgh today will report to the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston that a newer, minimally inv...